Compare Stocks: ABOS, SLN, IRWD, and AUTL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.55 +1.6%	$2.37	$1.21 ▼ $3.60	$181.29M	0.36	324,789 shs	449,053 shs
AUTL Autolus Therapeutics	$2.22 +4.7%	$1.63	$1.17 ▼ $2.43	$564.25M	2.07	2.49 million shs	2.24 million shs
IRWD Ironwood Pharmaceuticals	$4.08 -5.6%	$3.97	$1.01 ▼ $5.78	$704.41M	0.2	2.19 million shs	2.08 million shs
SLN Silence Therapeutics	$13.97 +2.9%	$9.94	$4.19 ▼ $17.58	$641.45M	1.39	1.69 million shs	2.81 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+1.59%	+11.84%	+0.79%	+11.84%	+100.79%
AUTL Autolus Therapeutics	+4.72%	+11.00%	+53.10%	+36.20%	+20.65%
IRWD Ironwood Pharmaceuticals	-5.56%	-4.23%	+2.51%	+13.97%	+274.31%
SLN Silence Therapeutics	+2.87%	+19.20%	+43.28%	+129.02%	+138.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.55 +1.6%	$2.37	$1.21 ▼ $3.60	$181.29M	0.36	324,789 shs	449,053 shs
AUTL Autolus Therapeutics	$2.22 +4.7%	$1.63	$1.17 ▼ $2.43	$564.25M	2.07	2.49 million shs	2.24 million shs
IRWD Ironwood Pharmaceuticals	$4.08 -5.6%	$3.97	$1.01 ▼ $5.78	$704.41M	0.2	2.19 million shs	2.08 million shs
SLN Silence Therapeutics	$13.97 +2.9%	$9.94	$4.19 ▼ $17.58	$641.45M	1.39	1.69 million shs	2.81 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+1.59%	+11.84%	+0.79%	+11.84%	+100.79%
AUTL Autolus Therapeutics	+4.72%	+11.00%	+53.10%	+36.20%	+20.65%
IRWD Ironwood Pharmaceuticals	-5.56%	-4.23%	+2.51%	+13.97%	+274.31%
SLN Silence Therapeutics	+2.87%	+19.20%	+43.28%	+129.02%	+138.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.33	Hold	$8.00	213.73% Upside
AUTL Autolus Therapeutics	2.88	Moderate Buy	$10.00	350.45% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	52.78% Upside
SLN Silence Therapeutics	2.83	Moderate Buy	$53.50	282.96% Upside

Current Analyst Ratings Breakdown

Latest ABOS, SLN, IRWD, and AUTL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	SLN Silence Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$25.00 ➝ $32.00
8/7/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
8/3/2026	AUTL Autolus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
7/31/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/30/2026	IRWD Ironwood Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/24/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
7/17/2026	SLN Silence Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	ABOS Acumen Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	AUTL Autolus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/1/2026	IRWD Ironwood Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/24/2026	SLN Silence Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.16 per share	N/A
AUTL Autolus Therapeutics	$75.39M	7.84	N/A	N/A	$0.67 per share	3.31
IRWD Ironwood Pharmaceuticals	$389.32M	1.71	$0.24 per share	16.78	($0.99) per share	-4.12
SLN Silence Therapeutics	$560K	1,178.47	N/A	N/A	$1.32 per share	10.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.86	N/A	N/A	N/A	N/A	-125.51%	-79.04%	N/A
AUTL Autolus Therapeutics	-$287.53M	-$1.09	N/A	N/A	N/A	-238.66%	-152.15%	-47.27%	10/29/2026 (Estimated)
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.30	N/A	N/A	33.36%	-58.38%	34.93%	N/A
SLN Silence Therapeutics	-$88.61M	-$1.28	N/A	N/A	N/A	-8,943.86%	-96.82%	-45.72%	N/A

Latest ABOS, SLN, IRWD, and AUTL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/11/2026	Q2 2026	AUTL Autolus Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	$38.56 million	$45.69 million
8/10/2026	Q2 2026	SLN Silence Therapeutics	-$0.1387	-$0.26	-$0.1213	-$0.27	$1.13 million	$0.14 million
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
5/15/2026	Q1 2026	AUTL Autolus Therapeutics	-$0.29	-$0.27	+$0.02	-$0.27	$26.27 million	$26.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.19	4.55	4.55
AUTL Autolus Therapeutics	N/A	5.80	5.28
IRWD Ironwood Pharmaceuticals	N/A	6.06	1.41
SLN Silence Therapeutics	N/A	9.83	9.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
AUTL Autolus Therapeutics	72.83%
IRWD Ironwood Pharmaceuticals	N/A
SLN Silence Therapeutics	98.73%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
AUTL Autolus Therapeutics	25.70%
IRWD Ironwood Pharmaceuticals	9.30%
SLN Silence Therapeutics	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	72.23 million	64.86 million	Optionable
AUTL Autolus Therapeutics	330	266.16 million	197.75 million	Optionable
IRWD Ironwood Pharmaceuticals	220	163.06 million	147.89 million	Optionable
SLN Silence Therapeutics	100	47.24 million	45.82 million	Not Optionable

ABOS, SLN, IRWD, and AUTL Headlines

Recent News About These Companies

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

August 13 at 10:56 AM | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Silence Therapeutics (SLN)

August 12 at 6:33 PM | theglobeandmail.com

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

August 12 at 6:33 PM | theglobeandmail.com

Silence Therapeutics (NASDAQ:SLN) Shares Down 6.9% - What's Next?

August 12 at 2:59 PM | marketbeat.com

Analysts Conflicted on These Healthcare Names: Silence Therapeutics (SLN), Hims & Hers Health (HIMS) and Syndax Pharmaceuticals (SNDX)

August 12 at 8:02 AM | theglobeandmail.com

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

August 11 at 11:20 PM | businesswire.com

Morgan Stanley maintains Overweight rating on Silence Therapeutics

August 11 at 7:57 PM | seekingalpha.com

Silence Therapeutics (NASDAQ:SLN) Sees Unusually-High Trading Volume - What's Next?

August 11 at 12:19 PM | marketbeat.com

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Analysts

August 11 at 3:17 AM | americanbankingnews.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera - Slideshow

August 11 at 2:02 AM | seekingalpha.com

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

August 11 at 1:00 AM | marketbeat.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

August 10, 2026 | seekingalpha.com

Silence Therapeutics' Divesiran to Treat Polychthemia Vera Meets Primary, Secondary Endpoints

August 10, 2026 | finance.yahoo.com

Silence Therapeutics stock surges as divesiran trial results fuel optimism

August 10, 2026 | seekingalpha.com

Silence Therapeutics says blood cancer trial delivers 'best-case outcome'

August 10, 2026 | msn.com

Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares

August 10, 2026 | businesswire.com

Silence Therapeutics (NASDAQ:SLN) Shares Gap Up - Still a Buy?

August 10, 2026 | marketbeat.com

Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

August 10, 2026 | businesswire.com

Silence Therapeutics (NASDAQ:SLN) Issues Earnings Results

August 10, 2026 | marketbeat.com

Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

August 10, 2026 | businesswire.com

Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera

August 9, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, SLN, IRWD, and AUTL Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$2.55 +0.04 (+1.59%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$2.55 0.00 (-0.04%)

As of 04:09 AM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Autolus Therapeutics NASDAQ:AUTL

$2.22 +0.10 (+4.72%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$2.20 -0.02 (-0.90%)

As of 06:37 AM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.08 -0.24 (-5.56%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$4.14 +0.06 (+1.47%)

As of 04:44 AM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Silence Therapeutics NASDAQ:SLN

$13.97 +0.39 (+2.87%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$14.08 +0.11 (+0.79%)

As of 06:38 AM Eastern

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABOS, SLN, IRWD, and AUTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABOS, SLN, IRWD, and AUTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABOS, SLN, IRWD, and AUTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, SLN, IRWD, and AUTL Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Autolus Therapeutics NASDAQ:AUTL

Ironwood Pharmaceuticals NASDAQ:IRWD

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABOS, SLN, IRWD, and AUTL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABOS, SLN, IRWD, and AUTL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABOS, SLN, IRWD, and AUTL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, SLN, IRWD, and AUTL Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Autolus Therapeutics NASDAQ:AUTL

Ironwood Pharmaceuticals NASDAQ:IRWD

Silence Therapeutics NASDAQ:SLN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools